CalciMedica, Inc. Common Stock
CALC Real Time Price USDRecent trades of CALC by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CALC's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
CALC Revenue by Segment or Geography
New patents grants
-
Patent Title: Compounds that modulate intracellular calcium Feb. 20, 2024
-
Patent Title: Pyrazine-containing compound Sep. 12, 2023
-
Patent Title: Pyrazine-containing compound Sep. 13, 2022
-
Patent Title: Pancreatitis treatment Apr. 26, 2022
-
Patent Title: Pyrazine-containing compound Apr. 13, 2021
-
Patent Title: Pyrazine-containing compound Nov. 03, 2020
-
Patent Title: Compounds that modulate intracellular calcium Jul. 07, 2020
-
Patent Title: Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury Nov. 19, 2019
-
Patent Title: Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury Sep. 24, 2019
-
Patent Title: Compounds that modulate intracellular calcium Jul. 02, 2019
-
Patent Title: Compounds that modulate intracellular calcium Jan. 02, 2018
-
Patent Title: Compounds that modulate intracellular calcium Apr. 04, 2017
-
Patent Title: Compounds that modulate intracellular calcium Dec. 06, 2016
-
Patent Title: Compounds that modulate intracellular calcium May. 31, 2016
-
Patent Title: Compounds that modulate intracellular calcium Sep. 01, 2015
-
Patent Title: Compounds that modulate intracellular calcium Jul. 28, 2015
-
Patent Title: Compounds that modulate intracellular calcium Jul. 14, 2015
-
Patent Title: Compounds that modulate intracellular calcium Mar. 17, 2015
-
Patent Title: Compounds that modulate intracellular calcium Jun. 17, 2014
-
Patent Title: Compounds that modulate intracellular calcium Dec. 31, 2013
-
Patent Title: Compounds that modulate intracellular calcium Oct. 01, 2013
-
Patent Title: Compounds that modulate intracellular calcium Sep. 03, 2013
-
Patent Title: Inhibitors of store operated calcium release Sep. 03, 2013
-
Patent Title: Calcium channel proteins and uses thereof Aug. 13, 2013
-
Patent Title: Compounds that modulate intracellular calcium Mar. 12, 2013
-
Patent Title: Compounds that modulate intracellular calcium Mar. 05, 2013
-
Patent Title: Trisubstituted thiophenes that modulate intracellular calcium Feb. 26, 2013
-
Patent Title: Trisubstituted thiophenes that modulate intracellular calcium Feb. 12, 2013
-
Patent Title: Methods of modulating and identifying agents that modulate intracellular calcium Dec. 04, 2012
-
Patent Title: Compounds that modulate intracellular calcium Sep. 11, 2012
-
Patent Title: Inhibitors of store operated calcium release Mar. 27, 2012
-
Patent Title: Compounds that modulate intracellular calcium Jul. 19, 2011
-
Patent Title: Substituted thiophene modulators of intracellular calcium Mar. 15, 2011
-
Patent Title: Methods of modulating and identifying agents that modulate intracellular calcium Oct. 26, 2010
-
Patent Title: Composition comprising a cell comprising a stim1 protein and an agent that modulates intracellular calcium and methods of use Jan. 12, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CALC
Recent picks made for CALC stock on CNBC
ETFs with the largest estimated holdings in CALC
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CALC stock a Buy, Sell, or Hold?
- What is the price target for $CALC stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CALC stock?
- Who owns the most shares of $CALC stock?
- What funds own $CALC stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CALC Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.